Published in Nephrol Dial Transplant on May 09, 2009
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol (2011) 2.59
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol (2013) 1.95
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol (2009) 1.51
Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol (2011) 1.42
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab (2013) 1.26
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res (2013) 1.17
Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail (2014) 1.15
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol (2012) 1.09
Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One (2013) 1.09
Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet (2013) 1.09
Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol (2011) 1.02
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens (2012) 1.01
Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc Diabetol (2013) 0.99
FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab (2014) 0.97
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis (2013) 0.96
FGF23 and the parathyroid glands. Pediatr Nephrol (2010) 0.95
Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients (2013) 0.93
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov (2015) 0.90
A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients. BMC Nephrol (2013) 0.90
Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study. Atherosclerosis (2014) 0.89
FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol (2013) 0.89
Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol (2013) 0.89
Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations. PLoS One (2013) 0.86
Phosphorus is associated with coronary artery disease in patients with preserved renal function. PLoS One (2012) 0.85
Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab (2011) 0.84
Is fibroblast growth factor 23 a harbinger of mortality in CKD? Pediatr Nephrol (2011) 0.84
Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease. PLoS One (2013) 0.83
Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab (2011) 0.82
Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol (2012) 0.82
Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One (2014) 0.82
A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol (2014) 0.81
Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol (2012) 0.80
Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One (2012) 0.80
From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease. Pediatr Nephrol (2013) 0.80
Clinical practice. Fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr (2010) 0.80
Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients. J Nephrol (2015) 0.79
Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatr Transplant (2010) 0.78
Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol (2015) 0.78
Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy. J Ren Nutr (2013) 0.78
The Role of the Osteocyte in Bone and Nonbone Disease. Endocrinol Metab Clin North Am (2016) 0.78
Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. Cardiovasc Diabetol (2015) 0.76
Significant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular disease. J Geriatr Cardiol (2015) 0.76
Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study. J Am Heart Assoc (2016) 0.75
Fibroblast Growth Factor-23-A Potential Uremic Toxin. Toxins (Basel) (2016) 0.75
Phosphocalcic Markers and Calcification Propensity for Assessment of Interstitial Fibrosis and Vascular Lesions in Kidney Allograft Recipients. PLoS One (2016) 0.75
Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. Curr Opin Nephrol Hypertens (2015) 0.75
Long term evolution of endothelial function during kidney transplantation. BMC Nephrol (2016) 0.75
High-Flux Hemodialysis Benefits Hemodialysis Patients by Reducing Serum FGF-23 Levels and Reducing Vascular Calcification. Med Sci Monit (2015) 0.75
Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT). Nephron (2016) 0.75
Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch (2016) 0.75
Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats. Clin Exp Nephrol (2013) 0.75
Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications? Wien Klin Wochenschr (2010) 0.75
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation (2009) 4.78
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J (2008) 4.42
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Insulin resistance and risk of congestive heart failure. JAMA (2005) 3.79
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Lung recruitment maneuver depresses central hemodynamics in patients following cardiac surgery. Intensive Care Med (2005) 2.94
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation (2009) 2.85
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension (2008) 2.83
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Visualisation and quantification of peri-operative myocardial infarction after coronary artery bypass surgery with contrast-enhanced magnetic resonance imaging. Eur Heart J (2004) 2.77
Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis (2009) 2.73
Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med (2013) 2.73
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (2012) 2.61
Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation (2007) 2.59
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab (2012) 2.58
Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol (2012) 2.48
Diurnal blood pressure pattern and risk of congestive heart failure. JAMA (2006) 2.44
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
Horizontal transfer of an adaptive chimeric photoreceptor from bryophytes to ferns. Proc Natl Acad Sci U S A (2014) 2.42
Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab (2003) 2.34
Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33
Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol (2007) 2.31
Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28
The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail (2005) 2.28
Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens (2007) 2.26
Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes (2011) 2.21
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A (2011) 2.14
Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10
Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr (2012) 2.10
Central and peripheral haemodynamic effects of hyperglycaemia, hyperinsulinaemia, hyperlipidaemia or a mixed meal. Clin Sci (Lond) (2003) 2.07
Emergency department triage scales and their components: a systematic review of the scientific evidence. Scand J Trauma Resusc Emerg Med (2011) 1.98
Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis (2009) 1.97
Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J (2007) 1.84
Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J (2009) 1.78
Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. J Hypertens (2004) 1.73
Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet (2013) 1.72
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int (2010) 1.70
The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med (2013) 1.70
Myocardial scars more frequent than expected: magnetic resonance imaging detects potential risk group. J Am Coll Cardiol (2006) 1.67
Circulating levels of persistent organic pollutants (POPs) and carotid atherosclerosis in the elderly. Environ Health Perspect (2012) 1.67
Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation (2004) 1.67
Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol (2013) 1.67
Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab (2012) 1.67
Polychlorinated biphenyls and organochlorine pesticides in plasma predict development of type 2 diabetes in the elderly: the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) study. Diabetes Care (2011) 1.66
A systematic review of triage-related interventions to improve patient flow in emergency departments. Scand J Trauma Resusc Emerg Med (2011) 1.63
Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. Clin Chem (2008) 1.62
The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Press Monit (2007) 1.62
Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation (2003) 1.62
Baroreceptor sensitivity is impaired in elderly subjects with metabolic syndrome and insulin resistance. J Hypertens (2006) 1.59
Three-point Dixon method enables whole-body water and fat imaging of obese subjects. Magn Reson Med (2010) 1.54
High intake of added sugar among Norwegian children and adolescents. Public Health Nutr (2004) 1.52
Overweight and obesity among Norwegian schoolchildren: changes from 1993 to 2000. Scand J Public Health (2005) 1.52
A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics (2003) 1.52
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol (2008) 1.51
Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens (2009) 1.51
Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol Immunother (2011) 1.50
Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. Hypertension (2013) 1.50
Risk stratification by 24-hour ambulatory blood pressure and estimated glomerular filtration rate in 5322 subjects from 11 populations. Hypertension (2012) 1.49
Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model. Crit Care Med (2009) 1.48
Interplay of overweight and insulin resistance on hypertension development. J Hypertens (2014) 1.48
Determinants of the ambulatory arterial stiffness index in 7604 subjects from 6 populations. Hypertension (2008) 1.48
Selective recruitment maneuvers for lobar atelectasis: effects on lung function and central hemodynamics: an experimental study in pigs. Anesth Analg (2006) 1.47
Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med (2009) 1.45